IL265342B2 - Use of pridofidine for the treatment of Rett syndrome - Google Patents

Use of pridofidine for the treatment of Rett syndrome

Info

Publication number
IL265342B2
IL265342B2 IL265342A IL26534219A IL265342B2 IL 265342 B2 IL265342 B2 IL 265342B2 IL 265342 A IL265342 A IL 265342A IL 26534219 A IL26534219 A IL 26534219A IL 265342 B2 IL265342 B2 IL 265342B2
Authority
IL
Israel
Prior art keywords
pridopidine
composition
subject
bdnf
administered
Prior art date
Application number
IL265342A
Other languages
English (en)
Hebrew (he)
Other versions
IL265342A (en
Original Assignee
Prilenia Neurotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prilenia Neurotherapeutics Ltd filed Critical Prilenia Neurotherapeutics Ltd
Publication of IL265342A publication Critical patent/IL265342A/en
Publication of IL265342B2 publication Critical patent/IL265342B2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
IL265342A 2016-09-16 2019-03-13 Use of pridofidine for the treatment of Rett syndrome IL265342B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662395854P 2016-09-16 2016-09-16
PCT/US2017/051803 WO2018053280A1 (en) 2016-09-16 2017-09-15 Use of pridopidine for treating rett syndrome

Publications (2)

Publication Number Publication Date
IL265342A IL265342A (en) 2019-05-30
IL265342B2 true IL265342B2 (en) 2023-06-01

Family

ID=61619744

Family Applications (1)

Application Number Title Priority Date Filing Date
IL265342A IL265342B2 (en) 2016-09-16 2019-03-13 Use of pridofidine for the treatment of Rett syndrome

Country Status (13)

Country Link
EP (2) EP3512506B1 (cg-RX-API-DMAC7.html)
JP (1) JP6977029B2 (cg-RX-API-DMAC7.html)
CN (1) CN109982686A (cg-RX-API-DMAC7.html)
AU (1) AU2017326013B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019005040A2 (cg-RX-API-DMAC7.html)
CA (1) CA3036984C (cg-RX-API-DMAC7.html)
DK (2) DK4005570T3 (cg-RX-API-DMAC7.html)
ES (2) ES2909557T3 (cg-RX-API-DMAC7.html)
HU (1) HUE058314T2 (cg-RX-API-DMAC7.html)
IL (1) IL265342B2 (cg-RX-API-DMAC7.html)
MX (1) MX388845B (cg-RX-API-DMAC7.html)
PL (2) PL3512506T3 (cg-RX-API-DMAC7.html)
WO (1) WO2018053280A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA122999C2 (uk) 2013-06-21 2021-02-03 Прайлінія Н'Юротерапьютікс Лтд. Застосування придопідину для лікування хвороби гантінгтона
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
EP3503890B1 (en) 2016-08-24 2024-12-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating dystonias
MX390627B (es) 2016-08-24 2025-03-21 Prilenia Neurotherapeutics Ltd Uso de pridopidina para el tratamiento de la disminucion funcional.
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
CN109982686A (zh) 2016-09-16 2019-07-05 普瑞尼亚医疗发展有限公司 普利多匹定用于治疗rett综合征的用途
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
BR112021015346A2 (pt) 2019-02-04 2021-10-05 Prilenia Neurotherapeutics Ltd. Uso de pridopidina de baixa dose para a doença de parkinson e outras doenças associadas ao parkinsonismo
CN116472043A (zh) * 2020-10-20 2023-07-21 普瑞尼亚神经治疗有限公司 普利多匹定和类似物用于治疗焦虑和抑郁的用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001046145A1 (en) * 1999-12-22 2001-06-28 A. Carlsson Research Ab New modulators of dopamine neurotransmission
WO2013086425A1 (en) * 2011-12-08 2013-06-13 IVAX International GmbH The hydrobromide salt of pridopidine
WO2015112601A1 (en) * 2014-01-22 2015-07-30 IVAX International GmbH Modified release formulations of pridopidine
WO2016138135A1 (en) * 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2584831C (en) 2004-10-13 2013-09-17 Neurosearch Sweden Ab Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine
JP2013536825A (ja) 2010-09-03 2013-09-26 イバックス・インターナショナル・ゲーエムベーハー ドパミン作動性安定化剤として有用なプリドピジンの重水素化類似体
US20130267552A1 (en) 2012-04-04 2013-10-10 IVAX International GmbH Pharmaceutical compositions for combination therapy
UA122999C2 (uk) 2013-06-21 2021-02-03 Прайлінія Н'Юротерапьютікс Лтд. Застосування придопідину для лікування хвороби гантінгтона
EP4282479A3 (en) * 2015-02-25 2024-02-21 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
CN109982686A (zh) 2016-09-16 2019-07-05 普瑞尼亚医疗发展有限公司 普利多匹定用于治疗rett综合征的用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001046145A1 (en) * 1999-12-22 2001-06-28 A. Carlsson Research Ab New modulators of dopamine neurotransmission
WO2013086425A1 (en) * 2011-12-08 2013-06-13 IVAX International GmbH The hydrobromide salt of pridopidine
WO2015112601A1 (en) * 2014-01-22 2015-07-30 IVAX International GmbH Modified release formulations of pridopidine
WO2016138135A1 (en) * 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LI W ET AL., BDNF DEREGULATION IN RETT SYNDROME, 15 April 2013 (2013-04-15) *

Also Published As

Publication number Publication date
CN109982686A (zh) 2019-07-05
JP2019532926A (ja) 2019-11-14
MX388845B (es) 2025-03-20
ES2909557T3 (es) 2022-05-09
ES2986807T3 (es) 2024-11-12
PL4005570T3 (pl) 2024-09-23
IL265342A (en) 2019-05-30
AU2017326013B2 (en) 2020-12-24
DK3512506T3 (da) 2022-04-19
DK4005570T3 (da) 2024-08-19
AU2017326013A1 (en) 2019-04-11
EP3512506A1 (en) 2019-07-24
EP4005570A1 (en) 2022-06-01
MX2019003069A (es) 2019-09-02
CA3036984C (en) 2023-07-18
HUE058314T2 (hu) 2022-07-28
PL3512506T3 (pl) 2022-05-30
JP6977029B2 (ja) 2021-12-08
WO2018053280A1 (en) 2018-03-22
CA3036984A1 (en) 2018-03-22
EP3512506A4 (en) 2020-05-27
EP4005570B1 (en) 2024-05-15
EP3512506B1 (en) 2022-01-26
BR112019005040A2 (pt) 2019-07-16

Similar Documents

Publication Publication Date Title
AU2017326013B2 (en) Use of pridopidine for treating Rett syndrome
JP5875191B2 (ja) Cmt及び関連障害を処置するための新たな組成物
AU2018342072B2 (en) Use of fenfluramine formulation in reducing number and frequencies of convulsive seizures in patient populations
US20190247333A1 (en) Method of reduction in convulsive seizure frequency
US20180328915A1 (en) Treatment of Neurological and Neurodevelopmental Diseases and Disorders Associated with Aberrant Ion Channel Expression and Activity
JP2010510314A (ja) 精神遅滞、ダウン症候群、脆弱x症候群および自閉症の治療方法
EP3887481A1 (en) A method of treating refractory epilepsy syndromes using fenfluramine enantiomers
KR20160037169A (ko) 레트 증후군 및 그를 위한 치료
WO2019067413A1 (en) USE OF A FENFLURAMINE FORMULATION TO REDUCE THE NUMBER AND FREQUENCIES OF CONVULSIVE CRISES IN PATIENT POPULATIONS
US20240398778A1 (en) Use of pridopidine for treating rett syndrome
JP7744419B2 (ja) レット症候群を治療するためのプリドピジンまたはその類似体の使用
HK40009961B (en) Use of pridopidine for treating rett syndrome
AU2021383325B2 (en) Use of pridopidine and analogs for treating rett syndrome
CN108601772A (zh) 用于治疗tdp-43蛋白质病的他克莫司